Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | HTR2B | P41595 | 6/20 | 0.35 |
| ▸ | PNMT | P11086 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 6/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684829 | 0.89 | PNMT (0.34) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL23735313 | 0.87 | HTR2A (0.35) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL19684600 | 0.84 | HTR6 (0.36) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL20778123 | 0.83 | HTR2A (0.35) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL19684784 | 0.81 | PNMT (0.40) | PNMTHTR6 | |
| SCHEMBL23735224 | 0.81 | HTR2C (0.35) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL17462475 | 0.80 | PNMT (0.37) | PNMTHTR6CYP1A2 | |
| SCHEMBL19684795 | 0.80 | PNMT (0.39) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL19678859 | 0.77 | HTR2A (0.35) | HTR2AHTR2CHTR2BPNMTHTR6 | |
| SCHEMBL19684792 | 0.77 | PNMT (0.37) | PNMTHTR6ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | HTR2A 4697/4885HTR2C 4759/4885HTR2B 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.